review · Journal of Clinical Oncology
Updated clinical practice guidance provides recommendations on sentinel lymph node biopsy and axillary lymph node dissection for early-stage breast cancer patients undergoing initial surgery. Routine sentinel node biopsy is not advised for select postmenopausal patients aged fifty and over with small, low-grade, hormone receptor-positive, HER2-negative tumours and negative preoperative ultrasound who receive breast-conserving therapy. Full axillary dissection should not be performed in patients without nodal spread, nor in those with one or two positive sentinel nodes receiving breast-conserving surgery and radiotherapy. For patients having mastectomies for clinically node-negative tumours up to five centimetres with one or two positive sentinel nodes, radiation can replace axillary dissection. Sentinel lymph node biopsy may also be offered to specific broader groups, including patients who are male, pregnant, obese, or have prior surgeries.
These updated guidelines clarify when invasive surgical procedures can be safely avoided during early-stage breast cancer management. By outlining precise clinical criteria for omitting sentinel lymph node biopsy and axillary dissection, the guidance helps reduce unnecessary surgical interventions, potentially lowering patient morbidity and procedural complications while standardising oncological care across surgical and radiation oncology teams.
This work represents clinical decision-making guidance ready for immediate adoption by oncology practitioners, hospital networks, and surgical teams. While it does not introduce a commercial product or device, it directly influences clinical protocols, care pathways, and healthcare resource allocation. Digital health developers and clinical decision support system providers could integrate these defined recommendation criteria into existing surgical oncology software platforms.
AI-generated from the published abstract. Always read the original work before citing.
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more. PURPOSE To update the ASCO evidence-based recommendations on the use of sentinel lymph node biopsy (SLNB) in patients with early-stage breast cancer treated with initial surgery. METHODS ASCO convened an Expert Panel to develop updated recommendations based on a systematic literature review (January 2016-May 2024). RESULTS Eleven randomized clinical trials (14 publications), eight meta-analyses and/or systematic reviews, and one prospective cohort study met the inclusion criteria for this systematic review. Expert Panel members used available evidence and informal consensus to develop practice recommendations. RECOMMENDATIONS Clinicians should not recommend routine SLNB in select patients who are postmenopausal and ≥50 years of age and with negative findings on preoperative axillary ultrasound for grade 1-2, small (≤2 cm), hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer and who undergo breast-conserving therapy. Clinicians may offer postmastectomy radiation (RT) with regional nodal irradiation (RNI) and omit axillary lymph node dissection (ALND) in patients with clinically node-negative invasive breast cancer ≤5 cm who receive mastectomy and have one to two positive sentinel nodes. Clinicians may offer SLNB in patients who have cT3-T4c or multicentric tumors (clinically node-negative) or ductal carcinoma in situ treated with mastectomy, and in patients who are obese, male, or pregnant, or who have had prior breast or axillary surgery. Clinicians should not recommend ALND for patients with early-stage breast cancer who do not have nodal metastases, and clinicians should not recommend ALND for patients with early-stage breast cancer who have one or two sentinel lymph node metastases and will receive breast-conserving surgery and whole-breast RT with or without RNI. Additional information is available at www.asco.org/breast-cancer-guidelines . This guideline has been endorsed by the American Society for Radiation Oncology (ASTRO).
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1200/jco-25-00099
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
